Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | GJB2 | P29033 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.36 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.36 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12420312 | 0.89 | SLC2A1 (0.40) | SLC2A1MAPK1L3MBTL1TNFGBA1 | |
| SCHEMBL12480998 | 0.89 | SLC2A1 (0.40) | SLC2A1MAPK1L3MBTL1TNFGBA1 | |
| SCHEMBL14413981 | 0.87 | MAPK1 (0.51) | SLC2A1MAPK1L3MBTL1TNFGBA1 | |
| SCHEMBL4201767 | 0.87 | SLC2A1 (0.57) | SLC2A1MAPK1TNFGBA1GJB2 | |
| SCHEMBL4195233 | 0.86 | SLC2A1 (0.46) | SLC2A1MAPK1TNFGBA1GJB2 | |
| SCHEMBL14885870 | 0.86 | GJB2 (0.43) | SLC2A1MAPK1L3MBTL1TNFGJB2 | |
| SCHEMBL4195236 | 0.86 | SLC2A1 (0.46) | SLC2A1MAPK1TNFGBA1GJB2 | |
| SCHEMBL14747620 | 0.83 | MAPK1 (0.52) | SLC2A1MAPK1L3MBTL1TNFGBA1 | |
| SCHEMBL15774181 | 0.82 | MAPK1 (0.54) | SLC2A1MAPK1L3MBTL1GBA1GJB2 | |
| SCHEMBL15774180 | 0.82 | MAPK1 (0.54) | SLC2A1MAPK1L3MBTL1GBA1GJB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100202971-A1 | COMPOUND HAVING TUMOR-RESIDENT PROPERTY | OHTA KEISUKE | 2010-08-12 | — | — | US | disclosed |
| WO-2010082634-A1 | COMPOUND RETAINED IN TUMOR | 東洋水産株式会社 (JP) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100202971-A1 | COMPOUND HAVING TUMOR-RESIDENT PROPERTY | HRH3, HRH4, HNRNPH3 | SLC2A1 2961/4885MAPK1 4810/4885L3MBTL1 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.